Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Treatment patterns and outcomes among patients treated with second-generation BTK inhibitors in CLL

View Full Paper
Ask AI
Bookmark
Share

Authors

XWXiaoliang WangGMGregory A. Maglinte

Discussion

Loading...

Member takes

Overview

Observational analysis revealed better survival with zanubrutinib than acalabrutinib in patients with CLL, suggesting treatment characterizations impact clinical outcomes.

Key Points

  • Patients treated with zanubrutinib had a lower likelihood of starting the next line of therapy than those on acalabrutinib.
  • Adverse events were reported in 97% of patients, with bleeding and fatigue being the most common issues encountered.
  • Binary comparisons between zanubrutinib and acalabrutinib revealed trends suggesting improved overall survival for zip, yet not statistically significant.
  • Comorbidities such as those tracked by the Charlson Comorbidity Index played a notable role in patient outcomes, affecting both treatment patterns and survival.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4cfhttps://doi.org/10.1182/blood-2025-4528
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Adverse event profiles of acalabrutinib and zanubrutinib in chronic lymphocytic leukemia: A real-world comparison2025 · 1 citations
  2. 2Real-world zanubrutinib treatment patterns in CLL/SLL among a curated sample of US community oncology patients with prior acalabrutinib therapy2025 · 1 citations
  3. 3Safety and efficacy of zanubrutinib in waldenstrom macroglobulinemia patients treated in common clinical practice: A retrospective-prospective study by fondazione italiana linfomi (FIL)2025
  4. 4Real-world chronic lymphocytic leukemia/small lymphocytic lymphoma treatment patterns at Florida cancer specialists & research institute among patients receiving zanubrutinib immediately following prior BTKi therapy2025
  5. 5Real world outcomes of zanubrutinib monotherapy for CLL/SLL focusing on treatment discontinuation and BTKi switching: A single center retrospective analysis2025